Risperidone extended release - Rovi
Alternative Names: DORIA®; Okedi; OKEDIMC; PrOKEDI; Risperidona ISM®; Risperidone-ISM®; RisvanLatest Information Update: 23 Jul 2026
At a glance
- Originator Rovi
- Class 2 ring heterocyclic compounds; Alkanes; Antidepressants; Antineoplastics; Antipsychotics; Behavioural disorder therapies; Benzoxazoles; Fluorinated hydrocarbons; Isoxazoles; Mood stabilisers; Piperidines; Pyridines; Pyrimidinones; Small molecules
- Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 5-HT2A receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Schizophrenia
Most Recent Events
- 23 Jul 2026 Launched for Schizophrenia (In adults) in Hungary, Denmark, Netherlands (IM) before July 2026
- 23 Jul 2026 Launched for Schizophrenia (In adults) in Norway (IM)
- 07 Jul 2025 Rovi completes in a phase I QUARTZ trial for Schizophrenia in Jordan (IM) (NCT06276361)